Respinova wins second Horizon 2020 Grant for top 1% of innovators. Read more here.
FDA Clears Pulsehaler for sale in the US.
Breathe Well, Live Well
CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD)
Chronic Obstructive Pulmonary Disease (COPD) affects 5-14% of the world population over 40 years of age. Our mission is to reverse the suffering of COPD patients, and provide them with renewed quality of life and hope for the future.
Over 384M Patients
Direct Healthcare Costs of $30B in the USA and €50B in Europe
3rd Leading Cause of Death
Pulsehaler™ is a novel treatment that uses Dynamic Air Pressure Pulses to facilitate the opening of airways and clearance of mucus.
LEADERSHIP
Yuval Avni, CTO
Serial Entrepreneur, Inventor and Product Developer
Need more details? Contact us
We are here to assist. Contact us by phone, email or via our social media channels.